Pharmacokinetic interaction between oral cyclosporin and mibefradil in stabilized post-renal-transplant patients

Nephrology Dialysis Transplantation

Volumn 13, Issue 7, 1998, Pages 1787-1791

  Spoendlin, Martin ^a   Peters, Juho ^b   Welker, Horst ^b   Bock, Andreas ^a   Thiel, Gilbert ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cyclosporin; Drug interaction; Mibefradil; Pharmackinetics; Transplant

Indexed keywords

CALCIUM ANTAGONIST; CYCLOSPORIN A; CYTOCHROME P450 ISOENZYME; MIBEFRADIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; KIDNEY TRANSPLANTATION; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AGED; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIBEFRADIL; MIDDLE AGED; TETRAHYDRONAPHTHALENES;

EID: 0031802051     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/13.7.1787     Document Type: Article

References (39)

1. Weir M. Therapeutic benefits of calcium channel blockers in cyclosporine-treated organ recipients: blood pressure control and immunosuppression. Am J Med 1991; 90 [Suppl 5A]: 32S-36S
2. Sketris I, Methot M, Nicol D, Belitsky P, Knox M. Effect of calcium-channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother 1994; 28: 1227-1231
3. Wagner K, Philipp T, Heinemeyer G, Brockmüller F, Roots I. Neumayer H. Interaction of cyclosporine and calcium antagonists. Transplant Proc 1989; 21: 1453-1456
4. Palmer B, Dawidson I, Sagalowsky A, Sandor Z, Lu C. Improved outcome of cadaveric renal transplantation due to calcium channel blockers. Transplantation 1991; 52: 640-645
5. Kunzendorf U, Walz G, Brockmoeller J et al. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 1991; 52: 280-284
6. Morales J, Andrés A, Alvarez C et al Calcium channel blockers and early cyclosporine nephrotoxicity after renal transplantation: a prospective randomized study. Transplant Proc 1990; 22: 1733-1735
7. Hauser A, Derfler K, Stockenhuber F, Wamser P, Marosi L, Balcke P. Effect of calcium-channel blockers on renal function in renal-graft recipients treated with cyclosporine (letter). N Engl J Med 1991; 324: 1517
8. Mandreoli M, Espositi E, Cocchi R, Fabbri A, Guerrini L, Fusaroli M. Do calcium channel blockers have any influence on the immunological status of renal graft recipients on cyclosporin therapy? Am J Nephrol 1990; 10: 58-60
9. Chitwood K, Heim-Duthoy K. Immunosuppressive properties of calcium channel blockers. Pharmacotherapy 1993; 13: 447-454
10. Donnelly P, Feehally J, Jurewicz A et al Renal transplantation: nifedipine for the nonstarters? A prospective randomized study. Transplant Proc 1993; 25: 600-601
11. Chrysostomou A, Walker R, Russ G, D'Apice A, Kincaid-Smith P, Mathew T. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993; 55: 300-304
12. McCauley J, Ptachcinski R, Shapiro R. The cyclosporine-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989; 21: 3955-3957
13. Campistol J, Oppenheimer F, Vilardell J et al Interaction between ciclosporin and diltiazem in renal transplant patients. Nephron 1991; 57: 241-242
14. 2+ channels by Ro 40 5967. Circ Res 1994; 75: 144-148
15. Clozel J-P, Banken L, Osterrieder W. Effects of Ro 40-5967, a novel calcium antagonist, on myocardial function during ischemia induced by lowering coronary perfusion pressure in dogs: comparison with verapamil. J Cardiovasc Pharmacol 1989; 14: 713-721
16. 2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990; 4: 731-736
17. Schmitt R, Kleinbloesem C, Belz G et al Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther 1992; 52: 314-323
18. Bernink P, Prager G, Schelling A, Kobrin I. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Hypertension 1996; 27: 426-432
19. Woittiez A, Huysmans F, Bailey R et al A comparison of the safety and efficacy of mibefradil and nifedipine SR in patients with renal disease and hypertension. Clin Nephrol 1998; 49: 107-114
20. Abernethy D. Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L-type calcium channel antagonist. Am J Cardiol 1997; 80: 4C-11C
21. Wu C, Benet L, Hebert M et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995; 58: 492-497
22. Benet L, Oie S, Schwartz J. Design and optimization of dosage regiments; pharmacokinetic data. In: Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 1996; 1707-1792
23. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24: 472-495
24. Kronbach T, Fischer V, Myer U. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43: 630-635
25. Combalbert J, Fabre I, Fabre G et al Metabolism of cyclosporine A. IV. Purification and identification of the rifampicininducible human liver cytochrome P450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207
26. Gomez D, Wacher V, Tomlanovich S, Herbert M, Benet L. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995; 58: 15-19
27. Lown KS, Mayo RR, Leichtman AB et al Role of intestinal P-glycoprotein (mdr-1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62: 248-260
28. Turgeon D, Leichtman A, Lown K et al. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994; 56: 253-260
29. Sewing K-F, Christians U, Kohlhaw K et al. Biologic activity of cyclosporine metabolites. Transplant Proc 1990; 22: 1129-1134
30. Tortorice K, Heim-Duthoy K, Awni W, Rao K, Kasiske B. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. Ther Drug Monit 1990; 12: 321-328
31. Lindholm A, Henricsson S. Verapamil inhibits cyclosporin metabolism. Lancet 1987: 1262-1263
32. Pochet J, Pirson Y. Cyclosporin-diltiazem interaction. Lancet 1986; 1: 979
33. Cantarovich M, Hiesse C, Lockiec F, Charpentier B, Fries D. Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients. Clin Nephrol 1987; 28: 190-193
34. Wagner K, Henkel M, Heinemeyer G, Neumayer H-H. Interaction of calcium blockers and cyclosporine. Transplant Proc 1988; 20 [Suppl. 2]: 561-568
35. Copur M, Tasdemir I, Turgan Ç, Yasavul Ü, Çablar S. Effects of nitrendipine on blood pressure and blood ciclosporin A level in patients with posttransplant hypertension. Nephron 1989; 52: 227-230
36. Endresen L, Bergan S, Holdaas H, Pran T, Sinding-Larsen B, Berg K. Lack of effect of the calcium antagonist isradipine on cyclosporine pharmacokinetics in renal transplant patients. Ther Drug Monit 1991; 13: 490-495
37. Martinez F, Pirson Y, Wallemacq P, van Ypersele de Strihou C. No clinically significant interaction between ciclosporin and isradipine. Nephron 1991; 59: 658-659
38. Abernethy D. The pharmacokinetic profile of amlodipine. Am Heart J 1989; 5: 1100-1103
39. Lindberg-Freijs A. The pharmacokinetics of cyclosporine A with special emphasis on bioavailability. Acta Pharm Nord 1992; 4: 189-191